Event: Wednesday, July 15, 2026, before market open; conference call at 8:30 a.m. ET. (investor.jnj.com)
JNJ enters 2Q with a constructive fundamental narrative: growth is broadening beyond the legacy portfolio, Innovative Medicine has multiple sizable launch assets, and MedTech is positioned to accelerate as cardiovascular platforms scale. The key debate is no longer whether JNJ can offset the STELARA erosion cycle; it is whether the company can sustain enough underlying growth and margin recovery to support its longer-term double-digit-growth aspiration.
The quarter should therefore be judged less on the headline EPS beat and more on four items:
Available market estimates point to:
| 2Q26 consensus | Estimate | YoY change |
|---|---|---|
| Revenue | $25.0B | +5.4% |
| Adjusted EPS | $2.86 | +3.2% |
| Innovative Medicine revenue | $16.1B | ~+6% |
| MedTech revenue | $8.9B | ~+5.3% |
The implied revenue increase is roughly $1.3B versus 2Q25. Consensus appears to anticipate a continued solid top line but comparatively modest EPS growth, making margins, launch spending, tariffs, and FX important swing factors.
JNJ reported 1Q26 sales of $24.1B, up 6.4% operationally, while adjusted operational sales growth was 5.3%. Innovative Medicine grew 7.4% operationally and MedTech grew 4.6%. Management raised its 2026 outlook to midpoint reported sales of $100.8B and adjusted EPS of $11.55. (investor.jnj.com)
The quality of growth was strong: excluding STELARA, management said company sales grew at a double-digit rate in 1Q. The counterweight was profitability: adjusted EPS fell to $2.70 from $2.77 in the prior year, reflecting front-loaded launch investment, unfavorable mix, acquisition-related costs, and MedTech tariff pressure.
That makes 2Q a useful test of management’s assertion that investment intensity would be heavier in the first half but that full-year adjusted pretax operating margin can still improve by at least 50 bps.
STELARA remains the largest visible headwind. In 1Q, sales fell 61.7% operationally, creating an approximately 920-bp drag on Innovative Medicine operational growth. The erosion is known; the question is whether performance of the growth portfolio continues to exceed expectations enough to neutralize it.
Products to watch:
A strong 2Q would show that the fast-growing brands—not simply favorable comparisons or M&A—are more than offsetting biosimilar and loss-of-exclusivity pressure.
ICOTYDE is arguably the most important new launch for sentiment. Management has characterized the once-daily oral IL-23 therapy as a potential future mega-brand, positioning it as a first-choice systemic option in plaque psoriasis, complementary to TREMFYA as a biologic option.
At the April call, JNJ cited approximately 1,500 prescriptions written shortly after launch, across more than 1,000 unique prescribers. The crucial 2Q update is likely to be less about reported sales—given launch timing and access mechanics—and more about:
A strong access update could matter more for valuation than a small near-term sales beat.
INLEXZO’s bladder-cancer launch has begun well. Management said that after the April reimbursement J-code became effective, weekly new-patient insertions increased by more than 50% in the first week and nearly 90% in the second week.
The product is strategically important because it combines JNJ’s pharmaceutical and MedTech capabilities: drug innovation, reimbursement support, physician training, and procedure enablement. Investors should watch for:
MedTech grew 4.6% operationally in 1Q, and management described the quarter as seasonally subdued while reiterating confidence in better growth through 2026. The 2Q report should show whether that confidence is translating into improved execution.
Most important franchises:
After 1Q, JNJ guided to:
| FY26 guidance | Midpoint |
|---|---|
| Reported sales | $100.8B |
| Operational sales growth | 6.4% |
| Adjusted operational sales growth | 6.1% |
| Adjusted EPS | $11.55 |
| Adjusted EPS growth | 7.1% |
Management also noted that 2026 contains a 53rd week, contributing roughly 100 bps to full-year sales growth, with a larger benefit in 4Q.
Base case: JNJ reaffirms guidance after a solid quarter, framing 2H as increasingly supported by launch contributions and MedTech acceleration.
Bull case: A material revenue beat, accelerating launch KPIs, sustained cardiovascular strength, and evidence that investment intensity and tariffs are manageable create room for another guidance raise.
Bear case: Guidance is held because of a weaker-than-expected MedTech recovery, more severe STELARA pressure, launch-access friction, or a more persistent gross-margin drag from tariffs and mix.
JNJ’s 1Q adjusted pretax margin declined materially versus the prior year, with Innovative Medicine affected by launch spending and mix, and MedTech affected by tariffs and cost of goods sold. Management nonetheless retained its full-year outlook for at least 50 bps of adjusted pretax operating-margin expansion.
For 2Q, the most useful questions are:
Because consensus EPS growth is modest, even a modest margin upside could have an outsized impact on the earnings outcome and outlook.
JNJ looks positioned for a solid 2Q, but expectations have evolved beyond a routine beat-and-raise story. Investors need evidence that the company is simultaneously:
The most favorable outcome would pair revenue and EPS upside with concrete ICOTYDE and INLEXZO launch metrics, continued double-digit growth in core oncology/cardiovascular franchises, and either a guidance raise or notably firmer confidence in second-half margin expansion.